{
  "id": 16100949,
  "title": "Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development",
  "url": "https://urgent.news/2026/10/22/fortrea-and-omico-collaboration-to-advance-biomarker-led-oncology",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-22T20:12:57.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/fortrea-and-omico-collaboration-to-advance-biomarker-led-oncology-drug-development"
  },
  "original_language": "en",
  "account": null,
  "summary": "Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia Highlights Collaboration aims to accelerate precision oncology research in Australia Combines Fortrea’s experience in oncology clinical trials with Omico’s Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) program Together, Fortrea and Omico offer more efficient…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}